Inhibrx Biosciences, Inc. — fact timeline

Inhibrx Biosciences, Inc. shareholders approved Ratification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.

“Proposal 2 Ratification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained 11,510,478 30,347 407”

Inhibrx Biosciences, Inc. shareholders approved Election of the following nominees as Class II directors of the Company at the 2026-06-03 meeting.

“Proposal 1 Election of the following nominees as Class II directors of the Company, nominated by the Company’s Board of Directors (the “Board of Directors”), each to serve until the 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified, or until their respective earlier death, resignation, or removal. Votes For Votes Withheld Broker Non-Votes Douglas G. Forsyth 7,608,469 1,463,474 2,469,289 Kimberly Manhard 9,035,097 36,846 2,469,289”

Inhibrx Biosciences, Inc. reported the first quarter of 2026 results: net income $33.4 million, EPS $2.15 per share.

“Net loss was $33.4 million during the first quarter of 2026, or $2.15 per share, basic and diluted”

Inhibrx Biosciences, Inc. reported the fourth quarter and fiscal year 2025 results: net income Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1.

“Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results”

Mark Lappe changed role as Chief Executive Officer and Chairperson of the Board at Inhibrx Biosciences, Inc..

“Mark Lappe will continue in his roles as Chief Executive Officer and Chairperson of the Board of Directors, but will no longer hold the title of President.”

Brendan P. Eckelman resigned as EVP, Chief Scientific Officer at Inhibrx Biosciences, Inc..

“On March 31, 2025, Brendan P. Eckelman, Ph.D. informed the Company of his intention to resign as EVP, Chief Scientific Officer of the Company, effective immediately, to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.”

David J. Matly was appointed as President at Inhibrx Biosciences, Inc..

“On April 1, 2025, Inhibrx Biosciences, Inc. (the “Company”) announced the appointment of David J. Matly, M.B.A. as President, effective April 1, 2025, adding to his current role as Chief Commercial and Business Development Officer.”

Inhibrx Biosciences, Inc. underwent a change of control involving Inhibrx, Inc. (closed 2024-05-29).

“On May 29, 2024, Inhibrx, Inc., a Delaware corporation (“RemainCo”), completed the distribution of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), to holders of shares of RemainCo’s common stock as of the distribution record date of May 17, 2024, on a pro rata basis (the “Distribution”), at a ratio of one share of the Company’s common stock for every four shares of RemainCo’s issued and outstanding common stock held on the distribution record date.”